The Knight Anole (Anolis equestris) in Florida

In this paper, we discuss the likely modes of introduction of the Knight Anole (Anolis equestris) into and around Florida, provide data on its current geographic distribution, and summarize life history data in both its native and introduced Florida range. Our field data consist of collections made from 1992 through 2008 and locality data taken from the literature and systematic collections throughout the United States. Anolis equestris was first introduced in Miami-Dade County in 1952. The subsequent spread of this species in Florida has been both natural and assisted by human translocations to 10 additional counties, including Brevard, Broward, Collier, Highlands, Lee, Martin, Monroe, Palm Beach, Polk, and St. Lucie. Because this species is nonindigenous and known to consume a wide variety of items, including small vertebrates, it should be removed when encountered in the wild. A comprehensive study detailing its effects on the environment is needed

The Knight Anole (Anolis equestris) in Florida

In this paper, we discuss the likely modes of introduction of the Knight Anole (Anolis equestris) into and around Florida, provide data on its current geographic distribution, and summarize life history data in both its native and introduced Florida range. Our field data consist of collections made from 1992 through 2008 and locality data taken from the literature and systematic collections throughout the United States. Anolis equestris was first introduced in Miami-Dade County in 1952. The subsequent spread of this species in Florida has been both natural and assisted by human translocations to 10 additional counties, including Brevard, Broward, Collier, Highlands, Lee, Martin, Monroe, Palm Beach, Polk, and St. Lucie. Because this species is nonindigenous and known to consume a wide variety of items, including small vertebrates, it should be removed when encountered in the wild. A comprehensive study detailing its effects on the environment is needed

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions.

ObjectiveTo determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk.MethodsBreast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg intravenous once or twice while breastfeeding from November 2017 to April 2019. Serial breast milk samples were collected before infusion and at 8 hours, 24 hours, 7 days, and 18-21 days after rituximab infusion in 4 patients. Five additional patients provided 1-2 samples at various times after rituximab infusion.ResultsThe median average rituximab concentration in mature breast milk was low at 0.063 μg/mL (range 0.046-0.097) in the 4 patients with serial breast milk collection, with an estimated median absolute infant dose of 0.0094 mg/kg/d and a relative infant dose (RID) of 0.08% (range 0.06%-0.10%). Most patients had a maximum concentration at 1-7 days after infusion. The maximum concentration occurred in a woman with a single breast milk sample and was 0.29 μg/mL at 11 days postinfusion, which corresponds with an estimated RID of 0.33%. Rituximab concentration in milk was virtually undetectable by 90 days postinfusion.ConclusionsWe determined minimal transfer of rituximab into mature breast milk. The RID for rituximab was less than 0.4% and well below theoretically acceptable levels of less than 10%. Low oral bioavailability would probably also limit the absorption of rituximab by the newborn. In women with serious autoimmune neurologic conditions, monoclonal antibody therapy may afford an acceptable benefit to risk ratio, supporting both maternal treatment and breastfeeding

Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ3

AbstractA series of novel RGD mimetics containing phthalimidine fragment was designed and synthesized. Their antiaggregative activity determined by Born’s method was shown to be due to inhibition of fibrinogen binding to αIIbβ3. Molecular docking of RGD mimetics to αIIbβ3 receptor showed the key interactions in this complex, and also some correlations have been observed between values of biological activity and docking scores. The single crystal X-ray data were obtained for five mimetics